Yayın: Efficacy of sunitinib in patients with imatinib-resistant gastrointestinal stromal tumors
Tarih
Kurum Yazarları
Kanat, Özkan
Ölmez, Ömer Fatih
Canhoroz, Mustafa
Avcı, Nilüfer
Hartavi, Mustafa
Seyhan, Serdar
Ayyıldız, Aylin
Yazarlar
Çubukcu, Sinem
Kanat, Özkan
Çubukcu, Erdem
Ölmez, Ömer Fatih
Canhoroz, Mustafa
Avcı, Nilüfer
Hartavi, Mustafa
Deligönül, Adem
Seyhan, Serdar
Ayyıldız, Aylin
Danışman
Dil
Türü
Yayıncı:
Derman Medical Publ
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Özet
Aim: In this study, the efficacy of sunitinib in patients with imatinib-resistant gastrointestinal stromal tumors (GISTs) was investigated. Material and Method: A total of 11 imatinib-resistant GIST patients who have sufficient information about their medical treatment and outcome were retrospectively analyzed. Results: Partial response was observed in only two patients, and five patients achieved stable disease. Progression free survival and overall time was 8.8 months and 12 months, respectively. Sunitinib was relatively well tolerated. Almost all patients experienced one or more treatment-related adverse event. Discussion: Based on our limited experience, we concluded that sunitinib is reasonable treatment option for patients with imatinibresistant GIST.
Açıklama
Kaynak:
Anahtar Kelimeler:
Konusu
Cancer, Sunitinib, Gastrointestinal stromal tumors, General & internal medicine